CVS Health Corporation (NYSE:CVS)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Monday.

Several other research analysts have also weighed in on the stock. Vetr raised shares of CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $87.97 price objective on the stock in a research note on Wednesday, May 24th. Tigress Financial assumed coverage on shares of CVS Health Corporation in a report on Thursday, April 27th. They set a “buy” rating on the stock. Evercore ISI restated an “outperform” rating and set a $88.00 target price (up from $87.00) on shares of CVS Health Corporation in a report on Wednesday, May 3rd. Cowen and Company restated an “outperform” rating and set a $86.00 target price on shares of CVS Health Corporation in a report on Tuesday, June 13th. Finally, ValuEngine downgraded shares of CVS Health Corporation from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Nine research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $93.98.

Shares of CVS Health Corporation (NYSE CVS) opened at 80.46 on Monday. CVS Health Corporation has a 12-month low of $69.30 and a 12-month high of $98.66. The stock’s 50 day moving average is $78.46 and its 200-day moving average is $79.38. The firm has a market cap of $81.97 billion, a price-to-earnings ratio of 16.78 and a beta of 0.91.

CVS Health Corporation (NYSE:CVS) last released its quarterly earnings data on Tuesday, May 2nd. The pharmacy operator reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.07. CVS Health Corporation had a net margin of 2.86% and a return on equity of 17.56%. The business had revenue of $44.51 billion for the quarter, compared to analyst estimates of $44.20 billion. During the same quarter last year, the firm earned $1.18 EPS. CVS Health Corporation’s quarterly revenue was up 3.0% compared to the same quarter last year. On average, analysts anticipate that CVS Health Corporation will post $5.87 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/03/guggenheim-reaffirms-buy-rating-for-cvs-health-corporation-cvs.html.

In other CVS Health Corporation news, CFO David M. Denton sold 230,510 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $80.00, for a total transaction of $18,440,800.00. Following the completion of the transaction, the chief financial officer now owns 176,983 shares of the company’s stock, valued at $14,158,640. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Helena Foulkes sold 20,332 shares of the business’s stock in a transaction dated Monday, June 19th. The stock was sold at an average price of $76.98, for a total value of $1,565,157.36. Following the transaction, the executive vice president now directly owns 59,300 shares of the company’s stock, valued at approximately $4,564,914. The disclosure for this sale can be found here. In the last three months, insiders have sold 271,175 shares of company stock valued at $21,632,597. Insiders own 0.61% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of CVS. Keel Point LLC increased its position in shares of CVS Health Corporation by 0.7% in the first quarter. Keel Point LLC now owns 3,296 shares of the pharmacy operator’s stock valued at $259,000 after buying an additional 22 shares during the last quarter. First City Capital Management Inc. increased its position in CVS Health Corporation by 0.3% in the first quarter. First City Capital Management Inc. now owns 12,771 shares of the pharmacy operator’s stock valued at $1,003,000 after buying an additional 40 shares in the last quarter. Lebenthal Asset Management LLC increased its position in CVS Health Corporation by 0.7% in the fourth quarter. Lebenthal Asset Management LLC now owns 6,557 shares of the pharmacy operator’s stock valued at $517,000 after buying an additional 48 shares in the last quarter. Valley National Advisers Inc. increased its position in CVS Health Corporation by 2.9% in the first quarter. Valley National Advisers Inc. now owns 1,696 shares of the pharmacy operator’s stock valued at $133,000 after buying an additional 48 shares in the last quarter. Finally, Alpha Windward LLC increased its position in CVS Health Corporation by 1.5% in the first quarter. Alpha Windward LLC now owns 3,302 shares of the pharmacy operator’s stock valued at $259,000 after buying an additional 49 shares in the last quarter. 81.99% of the stock is owned by hedge funds and other institutional investors.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.